

ESMO SARCOMA & GIST

10TH SPAEN MEETING - DESMOID TRACK DESMOID GLOBAL CONSENSUS

SPAEN & DTRF & EORTC / STBSG

Prof. Dr. med. Bernd Kasper

Mannheim University Medical Center, Mannheim, Germany

on behalf of **The Desmoid Tumor Working Group**



esmo.org

Background



- Desmoid tumour proliferation is unpredictable
- The incidence in the general population per 100,000 is low
- There was no standard approach for DTF in the conducted studies
- Initially, The Desmoid Position Paper in 2006 was based on a joint Roundtable Meeting in Heidelberg, Germany.

* Kasper B et al. Eur J Cancer 2017

REVIEW

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

B. Kasper^{1*}, C. Baumgarten², J. Garcia², S. Bonvalot³, R. Haas^{4,5}, F. Haller⁶, P. Hohenberger¹, N. Penel⁷, C. Messiou⁸, W. T. van der Graaf⁹ & A. Gronchi^{10*}, on behalf of the Desmoid Working Group[†]

¹Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center, University of Heidelberg, Mannheim; ²SPAEN Sarcoma Patients EuroNet e.V., Wölferstheim, Germany; ³Department of Surgical Oncology, Institut Curie, PSL University, Paris, France; ⁴Department of Radiotherapy, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam; ⁵Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands; ⁶Institute of Pathology, Friedrich Alexander University Erlangen, Erlangen, Germany; ⁷Department of Medical Oncology, Centre Oscar Lambret, Lille, France; ⁸Department of Radiology, The Royal Marsden Hospital, London; ⁹Division of Clinical Studies, The Institute of Cancer Research, London, UK; ¹⁰Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*Correspondence to: Prof. Bernd Kasper, Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. Tel: +49-621-383-2580; E-mail: bernd.kasper@umm.de

Dr Alessandro Gronchi, Department of Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Tel: +39-02-23-90-32-34; E-mail: alessandro.gronchi@istitutotumori.mi.it

[†]Additional Members of Desmoid Working Group are listed in the Acknowledgements.

Annals of Oncology 28: 2399–2408, 2017
doi:10.1093/annonc/mdx323
Published online 23 June 2017



Sarcoma
Patients
EuroNet



desmoid-type fibromatosis: a European Consensus Initiative based on patients' and Physicians EuroNet and EORTC/STBSG and Treatment of Cancer Group initiative

Haas^d, F. Haller^e, P. Hohenberger^a, et al^h, on behalf of the Desmoid Working Group



EORTC
European Organization for Research
and Treatment of Cancer



European
Reference
Network
for rare or low prevalence
complex diseases

Network
Adult Cancers
(ERN EURACAN)

The Desmoid Tumor Working Group went global!



18th of June 2018, Istituto Nazionale dei Tumori, Milan, Italy



Medizinische Fakultät Mannheim
der Universität Heidelberg
Universitätsklinikum Mannheim



Desmoid Meeting 2018 - Topics Covered

- Pathology & Molecular Genetics
- Indications for an Active Treatment incl. Radiotherapy
- **Available Medical Therapies in Different Indications**
- **Assessment of Treatment Effects**
- Pain, Quality of Life, Fertility & Pregnancy
- Which Endpoints, Study Designs & Regulatory Requirements do we need for Desmoids?



THE DESMOID TUMOR
RESEARCH FOUNDATION



Sarcoma
Patients
EuroNet



European
Reference
Network

for rare or low prevalence
complex diseases

 Network

Adult Cancers
(ERN EURACAN)




EORTC

European Organization for Research
and Treatment of Cancer

Desmoid Global Consensus - Publications

The Management of Desmoid Tumors:
A joint global evidence-based consensus guideline
approach for adult and pediatric patients



The Desmoid Tumor Working Group

Supported by:



Volume 118, September 2019

ISSN 0959-8049


EJC
EUROPEAN JOURNAL OF CANCER

IN THIS ISSUE


Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial

A validated prognostic classifier for ^{1000f}BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study



The Management of Desmoid Tumors: A joint global evidence-based consensus guideline approach for adult and pediatric patients



The Desmoid Tumor Working Group

Supported by:



The Desmoid Tumor Working Group:

B. Alman, University of Toronto, Canada
 S. Arta, Mayo Clinic, Jacksonville, Florida, USA
 C. Baumgarten, SOS Desmoid & Sarcoma Patients EuroNet (SPAEN)
 C. Benson, Royal Marsden Hospital London, London, UK
 J.Y. Blay, Centre Léon Bérard & University 'Cl. Bernard' Lyon I, EURACAN, LYRICAN, Lyon, France
 S. Bonvalot, Institut Curie, Paris, France
 J. Breuing, Institute for research in operative medicine, Witten/Herdecke, Germany
 K. Cardona, Winship Cancer Institute, Emory University, Atlanta, Ga, USA
 P.G. Casali, Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan, Milan, Italy
 F. van Coevorden, The Netherlands Cancer Institute, Amsterdam, The Netherlands
 C. Colombo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 A.P. Dei Tos, University of Padua School of Medicine, Padua, Italy
 P. Dileo, University College Hospital, UCLH NHS Trust, London, UK
 A. Ferrari, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 M. Fiore, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 A.M. Frezza, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 J. Garcia, Sarcoma Patients EuroNet (SPAEN)
 R. Gladly, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, Canada
 M. Gounder, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA
 A. Gronchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 R. Haas, The Netherlands Cancer Institute, Amsterdam, NL
 S. Hockett, Sarcoma UK Nurse, London, UK
 F. Haller, Friedrich Alexander University Erlangen, Erlangen, Germany
 P. Hohenberger, Mannheim University Medical Center, Mannheim, Germany
 O. Husson, The Institute of Cancer Research, London, UK and The Netherlands Cancer Institute, Amsterdam, The Netherlands
 R.L. Jones, Royal Marsden Hospital London and Institute of Cancer Research, London, UK
 I. Judson, Royal Marsden Hospital London, London, UK
 B. Kasper, Mannheim University Medical Center, Mannheim, Germany
 A. Kawai, National Cancer Center Hospital, Tokyo, Japan
 V. Kogovos, Mannheim University Medical Center, Mannheim, Germany
 A.J. Lazar, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
 R. Maki, Northwell Health Cancer Institute, New York, USA
 T. Mathes, Institute for research in operative medicine, Witten/Herdecke, Germany
 C. Messiou, Royal Marsden Hospital London, London, UK
 F. Navid, Children's Hospital Los Angeles, University of Southern California, Los Angeles, USA
 Y. Nishida, Nagoya University Graduate School of Medicine, Nagoya, Japan
 E. Palassini, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 N. Penel, Centre Oscar Lambret, Lille, France
 R. Pollock, The Ohio State University Comprehensive Cancer Center, Ohio, USA
 D. Pieper, Institute for research in operative medicine, Witten/Herdecke, Germany
 M. Portnoy, The Desmoid Tumor Research Foundation (DTRF)
 C.P. Raut, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
 E. Roets, Sarcoma Patients EuroNet (SPAEN)
 S. Sandrucci, CDSS University Hospital, Torino, Italy
 M. Sbaraglia, Azienda ULSS2 Marca Trevigiana, Treviso, Italy
 S. Stacchiotti, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
 K. Thornton, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
 W. van der Graaf, The Institute of Cancer Research, London, UK
 K. van der Zande, Sarcoma Patients EuroNet (SPAEN)
 W. J. van Houdt, The Netherlands Cancer Institute, Amsterdam, NL
 V. Villalobos, Division of Medical Oncology, University of Colorado, USA
 A.J. Wagner, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
 E. Wartenberg, University Hospital Muenster, Muenster, Germany
 M. Wartenberg, Sarcoma Patients EuroNet (SPAEN), Wölferheim, Germany
 S. Wotton, Institut Curie, Paris, France
 A. Weiss, Paediatric Oncology, Maine Medical Center, Portland, USA
 N. Zafiroopoulos, European Medicines Agency, London, UK

CHALLENGES IN EXPLOITING AND ASSESSING MEDICAL THERAPY FOR DESMOID TUMORS

SPAEN & DTRF & EORTC / STBSG

Prof. Dr. med. Bernd Kasper

Mannheim University Medical Center, Mannheim, Germany

on behalf of **The Desmoid Tumor Working Group**

Thank you!

